Topic

All

28
Apr
2021

Rare Side Effects of Adenovirus Vaccines Call for Careful Surveillance

Clinical trials have given us a wealth of information about the effectiveness, and safety profile, of vaccines for COVID-19. But the work of gathering evidence, and weighing the results in the context of an ongoing pandemic, isn’t done. The importance of developing population-based effectiveness and safety profiles associated with a mass vaccination campaign — the sort of deep datasets that...
Read More
27
Apr
2021

Quantified Self Redux?

The first iteration of the “Quantified Self” movement largely fizzled out about five years ago. Avid self-trackers, at the time, started to worry they were drowning in data, but lacking in insight.  Today, we seem to be entering Quantified Self 2.0. Once again, an expanding assortment of consumer devices promises to measure every parameter of our health and well-being.  The...
Read More
26
Apr
2021

Liberating Founders and Investors From Narrative Bias

We’re drawn to stories. We understand the world through stories – both the narratives we read, and those we create and develop for ourselves. It’s the very power – the unreasonable effectiveness? – of stories that also leaves us so vulnerable to deception, including self-deception. This is a key message from “Super Founders,” Ali Tamaseb’s soon-to-be-published analysis of the factors...
Read More
5
Apr
2021

The Glory of John Martin: an Understated Leader Who Built a Biotech Powerhouse

John C. Martin was an unassuming man with an ordinary name. But his leadership qualities and accomplishments as a biopharma CEO were extraordinary. Martin, the CEO of Foster City, Calif.-based Gilead Sciences from 1996 to 2016, didn’t seek to dominate the room or inspire legions with a charismatic personality. He didn’t make the cover of magazines, even when he led...
Read More
1 2 3 49